Atara Biotherapeutics Inc
SWB:AT2
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
A
|
Atara Biotherapeutics Inc
SWB:AT2
|
US |
|
S
|
Sempra Energy
F:SE4
|
US |
|
Y
|
Yum! Brands Inc
SWB:TGR
|
US |
|
C
|
China Literature Ltd
F:C2X
|
CN |
|
T
|
Trinity Ltd
F:7TR
|
HK |
|
CY4GATE SpA
F:68H
|
IT |
|
E
|
Eni SpA
XHAM:ENI
|
IT |
|
A
|
Akwel SA
F:MW4
|
FR |
|
D
|
Dnb ASA
OTC:DNBBF
|
NO |
|
S
|
SNP Schneider Neureither & Partner SE
DUS:SHF
|
DE |
|
DBS Group Holdings Ltd
OTC:DBSDF
|
SG |
|
Macy's Inc
NYSE:M
|
US |
|
Galapagos NV
AEX:GLPG
|
BE |
|
O
|
Once Upon A Farm PBC
NYSE:OFRM
|
US |
|
D
|
Dai-ichi Life Holdings Inc
XMUN:QHH
|
JP |
|
InnoTec TSS AG
F:TSS
|
DE |
|
A
|
Asics Corp
XBER:ASI1
|
JP |
Wall St Price Targets
AT2 Price Targets Summary
Atara Biotherapeutics Inc
According to Wall Street analysts, the average 1-year price target for AT2 is 10.5268 EUR with a low forecast of 7.627 EUR and a high forecast of 14.2723 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is AT2's stock price target?
Price Target
10.5268
EUR
According to Wall Street analysts, the average 1-year price target for AT2 is 10.5268 EUR with a low forecast of 7.627 EUR and a high forecast of 14.2723 EUR.
What is the Revenue forecast for Atara Biotherapeutics Inc?
Projected CAGR
-53%
The compound annual growth rate for Revenue over the next 3 years is -53%.
What is the Gross Profit forecast for Atara Biotherapeutics Inc?
Projected CAGR
-51%
The compound annual growth rate for Gross Profit over the next 3 years is -51%.
